Simon Vanveggel

4.7k citations

43 papers · 1.8k · h-index 21

Impact in

Virology top 0.5%
- HIV Research and Treatment
Infectious Diseases top 1%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Infectious Diseases 40
- HIV/AIDS drug development and treatment 40
- HIV/AIDS Research and Interventions 23
Virology 32
- HIV Research and Treatment 32

Co-authors: Katia Boven (17 shared papers)L Rimsky (12 shared papers)Herta Crauwels (14 shared papers)Jean‐Michel Molina (10 shared papers)Beatriz Grinsztejn (5 shared papers)Calvin Cohen (5 shared papers)Anthony Mills (7 shared papers)Kiat Ruxrungtham (3 shared papers)
Journals: Journal of the International AIDS Society (7 papers)AIDS (5 papers)HIV Medicine (3 papers)Antiviral Therapy (3 papers)Antimicrobial Agents and Chemotherapy (2 papers)
Partner nations: Belgium United States United Kingdom

In The Last Decade

Simon Vanveggel

42 papers receiving 1.8k citations

Peers

Countries citing papers authored by Simon Vanveggel

Since Specialization

Citations

This map shows the geographic impact of Simon Vanveggel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Vanveggel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Vanveggel more than expected).

Fields of papers citing papers by Simon Vanveggel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Vanveggel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Vanveggel. The network helps show where Simon Vanveggel may publish in the future.

Co-authors

The 25 scholars most cited alongside Simon Vanveggel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Simon Vanveggel Line = papers co-authored together Simon Vanveggel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial The Lancet ·Jean‐Michel Molina, Pedro Cahn, Beatriz Grinsztejn, Adriano Lazzarin, Anthony Mills, Michael S. Saag, Khuanchai Supparatpinyo, Sharon Walmsley, Herta Crauwels, L Rimsky, Simon Vanveggel, Katia Boven	2011	315
2	Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial The Lancet ·Calvin Cohen, Jaime Andrade‐Villanueva, Bonaventura Clotet, Jan Fourie, Margaret Johnson, Kiat Ruxrungtham, Hao Wu, Carmen Zorrilla, Herta Crauwels, L Rimsky, Simon Vanveggel, Katia Boven	2011	286
3	A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. PubMed ·Robert D. McQuade, Elyse Stock, R.N. Marcus, D. Jody, Neveen A. Gharbia, Simon Vanveggel, Д. Арчибалд, William H. Carson	2004	195
4	Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients JAIDS Journal of Acquired Immune Deficiency Syndromes ·Calvin Cohen, Jean‐Michel Molina, Pedro Cahn, Bonaventura Clotet, Jan Fourie, Beatriz Grinsztejn, Hao Wu, Margaret Johnson, Michael S. Saag, Khuanchai Supparatpinyo, Herta Crauwels, Éric Lefebvre, L Rimsky, Simon Vanveggel, Peter Williams, Katia Boven	2012	130
5	Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials AIDS ·Calvin Cohen, Jean‐Michel Molina, Isabel Cassetti, Ploenchan Chetchotisakd, Adriano Lazzarin, Chloe Orkin, Frank S. Rhame, Hans-Jürgen Stellbrink, Taisheng Li, Herta Crauwels, L Rimsky, Simon Vanveggel, Peter Williams, Katia Boven	2012	103
6	Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial AIDS ·Anton Pozniak, Javier O Morales-Ramirez, Elly Katabira, Dewald Steyn, Sergio Lupo, Mario Santoscoy, Beatriz Grinsztejn, Kiat Ruxrungtham, L Rimsky, Simon Vanveggel, Katia Boven	2009	89
7	A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients AIDS ·Joseph J. Eron, Chloe Orkin, Joel E. Gallant, Jean‐Michel Molina, Eugènia Negredo, Andrea Antinori, Anthony Mills, Jacques Reynes, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, John Jezorwski, Simon Vanveggel, Magda Opsomer	2018	67
8	Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks AIDS and Behavior ·Miranda Murray, Antonio Antela, Anthony Mills, Jenny Huang, H. de Jager, Enrique Bernal, Johan Lombaard, Harold Katner, Sharon Walmsley, Marie-Aude Khuong-Josses, Krischan J Hudson, David Dorey, Sandy Griffith, William Spreen, Simon Vanveggel, Mark S. Shaefer, David M. Margolis, Vasiliki Chounta	2020	53
9	Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1–Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials Clinical Infectious Diseases ·Pablo Tebas, Michael Sension, José Ramón Arribas, Dan Duiculescu, Éric Florence, Chien‐Ching Hung, Timothy Wilkin, Simon Vanveggel, Marita Stevens, H. Deckx, (unknown)	2014	49
10	Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. PubMed ·Herta Crauwels, Rolf P. G. van Heeswijk, Marita Stevens, Annemie Buelens, Simon Vanveggel, Katia Boven, Richard M. W. Hoetelmans	2013	48
11	Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) Patient ·Vasiliki Chounta, Edgar T. Overton, Anthony Mills, Susan Swindells, P D Benn, Simon Vanveggel, Rodica Van Solingen‐Ristea, Yuanyuan Wang, Krischan J Hudson, Mark S. Shaefer, David A. Margolis, Kimberly Y. Smith, William Spreen	2021	47
12	Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies HIV Clinical Trials ·Mark Nelson, Richard Elion, C Cohen, Anthony Mills, Sally Hodder, Sorana Segal‐Maurer, Mark Bloch, Will Garner, Bill Guyer, Scott Williams, S.K. Chuck, Simon Vanveggel, H. Deckx, Marita Stevens	2013	46
13	Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized Trial AIDS Research and Human Retroviruses ·Aimee Wilkin, Anton Pozniak, Javier O Morales-Ramirez, Sergio Lupo, Mario Santoscoy, Beatriz Grinsztejn, Kiat Ruxrungtham, L Rimsky, Simon Vanveggel, on behalf of the TMC -C Katia Boven	2011	45
14	Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo) Antiviral Therapy ·David A. Wohl, Chloe Orkin, Manuela Doroana, José Henrique Pilotto, Somnuek Sungkanuparph, Patrick Yéni, Simon Vanveggel, H. Deckx, Katia Boven	2013	36
15	Effect of gender and race on the week 48 findings in treatment‐naïve, HIV‐1‐infected patients enrolled in the randomized, phase III trials ECHO and THRIVE HIV Medicine ·Sally Hodder, Keikawus Arastéh, Joseph de Wet, Joseph Gathe, Julian Gold, Princy Kumar, Lerato Mohapi, William R. Short, Herta Crauwels, Simon Vanveggel, Katia Boven	2012	35
16	Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment‐naïve, HIV‐1‐infected patients at 48 weeks HIV Medicine ·AM Mills, Andrea Antinori, Bonaventura Clotet, Jan Fourie, Gisella Herrera, Charles B. Hicks, JV Madruga, Simon Vanveggel, Marita Stevens, Katia Boven, (unknown)	2013	33
17	Pre-Existing Mutations in the Rilpivirine Phase Iii Trials Echo and Thrive: Prevalence and Impact on Virological Response Antiviral Therapy ·Johan Vingerhoets, L Rimsky, Veerle Van Eygen, Steven Nijs, Simon Vanveggel, Katia Boven, Gastón Picchio	2012	31
18	Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials Journal of Antimicrobial Chemotherapy ·Mark Nelson, G. Amaya, Nathan Clumeck, C Arns Da Cunha, D. Jayaweera, Patrice Junod, T. Li, Pablo Tebas, Marita Stevens, Annemie Buelens, Simon Vanveggel, Katia Boven, (unknown)	2012	30
19	Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis AIDS Patient Care and STDs ·Georg M. N. Behrens, Bart Rijnders, Mark Nelson, Chloe Orkin, Calvin Cohen, Anthony Mills, Richard Elion, Simon Vanveggel, Marita Stevens, L Rimsky, David Thorpe, Matthew Bosse, Kirsten White, Lijie Zhong, Jennifer DeMorin, Susan K. Chuck	2014	23
20	Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less AIDS ·Jean‐Michel Molina, Nathan Clumeck, Karla Redant, L Rimsky, Simon Vanveggel, Marita Stevens	2013	22

About Simon Vanveggel

Simon Vanveggel is a scholar working on Infectious Diseases, Virology, Epidemiology, Emergency Medicine and Pediatrics, Perinatology and Child Health, having authored 43 papers that have together received 1.8k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (40 papers), HIV Research and Treatment (32 papers), HIV/AIDS Research and Interventions (23 papers), HIV-related health complications and treatments (6 papers), Pharmacological Effects and Toxicity Studies (5 papers), Pneumocystis jirovecii pneumonia detection and treatment (4 papers), Viral-associated cancers and disorders (3 papers) and Hepatitis B Virus Studies (2 papers). The work is most often cited by research in Virology (1.1k citations), Infectious Diseases (1.5k citations), Emergency Medicine (370 citations), Psychiatry and Mental health (179 citations) and Hepatology (88 citations). Simon Vanveggel has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include Katia Boven, L Rimsky, Herta Crauwels, Jean‐Michel Molina, Beatriz Grinsztejn, Calvin Cohen, Anthony Mills, Kiat Ruxrungtham, Bonaventura Clotet and Jan Fourie. Their work appears in journals such as Journal of the International AIDS Society, AIDS, HIV Medicine, Antiviral Therapy and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Simon Vanveggel

Impact in

Papers in i

In The Last Decade

Simon Vanveggel

Peers

Countries citing papers authored by Simon Vanveggel

Fields of papers citing papers by Simon Vanveggel

All Works

About Simon Vanveggel

Explore authors with similar magnitude of impact

Papers in